董事介绍
注：董事持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Yonatan Malca | 男 | Independent Director | 59 | 10.38万美元 | 未持股 | 2026-03-27 |
| Miranda J. Toledano | 女 | Chief Executive Officer and Director | 49 | 0.15万美元 | 未持股 | 2026-03-27 |
| Sean Ellis | 男 | Independent Director | 51 | 9.45万美元 | 未持股 | 2026-03-27 |
| Haya Taitel | 女 | Independent Director | 63 | 9.87万美元 | 未持股 | 2026-03-27 |
| Steven D. Rubin | 男 | Independent Director | 65 | 未披露 | 未持股 | 2026-03-27 |
| Geno J. Germano | 男 | Chairman of the Board and Independent Director | 65 | 未披露 | 未持股 | 2026-03-27 |
高管介绍
注：高管持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Hillel Galitzer | 男 | Chief Operating Officer | 47 | 0.05万美元 | 未持股 | 2026-03-27 |
| Dana Yaacov Garbeli | 女 | Chief Financial Officer | 42 | 未披露 | 未持股 | 2026-03-27 |
| Miranda J. Toledano | 女 | Chief Executive Officer and Director | 49 | 0.15万美元 | 未持股 | 2026-03-27 |
| Gregory Burshtein | 男 | Chief of Research and Development | 49 | 0.05万美元 | 未持股 | 2026-03-27 |
董事简历
中英对照 | 中文 | 英文- Yonatan Malca
-
Yonatan Malca自2011年以来一直担任我们的董事会成员。他目前担任D.N.A Biomedical公司的首席执行官兼董事（2010年以来）。Malca先生还担任Arko Holdings Ltd.的董事。TASE:Arko，NextGen-BioMed Ltd.TASE:NXGN和Tamda Ltd.（TASE:TMDA），均为以色列上市公司。Malca先生还任职于多家私人公司的董事会，包括担任医疗器械公司CardioArt Technologies Ltd.和医疗器械公司Beamed Ltd.（D.N.A Biomedical的子公司）的董事会主席。Malca先生拥有以色列巴伊兰大学（Bar-Ilan University）的经济学和统计学学士学位以及巴伊兰大学（Bar Ilan University）的经济学和金融学硕士学位。
Yonatan Malca has served as a member of Entera Bio Ltd. Board since 2011. Mr. Malca currently serves as Chief Executive Officer and a director of NanoGohst Ltd. From 2009 to 2021, he served as Chief Executive Officer and a director of DNA Biomedical Solutions Ltd. (TASE: DNA). Mr. Malca also serves as a director of Jungo Connectivity Ltd. (TASE: JNGO) and Unicorn Technologies (TASE: UNCT), both Israeli public companies. He also serves as director of BeamMed Ltd, a private medical device company. He previously served as a director of Nextgen Biomed LTD. (TASE: NXGN) from July 2018 to April 2019, ARKO Holdings Ltd. from August 2014 to December 2020, and Tamda Ltd. from July 2016 to September 2020. Mr. Malca holds a B.A. in Economics and Statistics from Bar Ilan University and an M.A. in Economics and Finance from Bar Ilan University, Israel. - Yonatan Malca自2011年以来一直担任我们的董事会成员。他目前担任D.N.A Biomedical公司的首席执行官兼董事（2010年以来）。Malca先生还担任Arko Holdings Ltd.的董事。TASE:Arko，NextGen-BioMed Ltd.TASE:NXGN和Tamda Ltd.（TASE:TMDA），均为以色列上市公司。Malca先生还任职于多家私人公司的董事会，包括担任医疗器械公司CardioArt Technologies Ltd.和医疗器械公司Beamed Ltd.（D.N.A Biomedical的子公司）的董事会主席。Malca先生拥有以色列巴伊兰大学（Bar-Ilan University）的经济学和统计学学士学位以及巴伊兰大学（Bar Ilan University）的经济学和金融学硕士学位。
- Yonatan Malca has served as a member of Entera Bio Ltd. Board since 2011. Mr. Malca currently serves as Chief Executive Officer and a director of NanoGohst Ltd. From 2009 to 2021, he served as Chief Executive Officer and a director of DNA Biomedical Solutions Ltd. (TASE: DNA). Mr. Malca also serves as a director of Jungo Connectivity Ltd. (TASE: JNGO) and Unicorn Technologies (TASE: UNCT), both Israeli public companies. He also serves as director of BeamMed Ltd, a private medical device company. He previously served as a director of Nextgen Biomed LTD. (TASE: NXGN) from July 2018 to April 2019, ARKO Holdings Ltd. from August 2014 to December 2020, and Tamda Ltd. from July 2016 to September 2020. Mr. Malca holds a B.A. in Economics and Statistics from Bar Ilan University and an M.A. in Economics and Finance from Bar Ilan University, Israel.
- Miranda J. Toledano
-
MirandaJ.Toledano自2018年9月以来一直担任我们的董事会成员。Toledano女士担任Trigr Therapeutics（一家临床阶段免疫肿瘤公司，专注于双特异性抗体）的首席运营官/首席财务官。此前，从2016年9月至2017年8月，Toledano女士担任Sorrento Therapeutics NASDAQ:SRNE的执行管理团队执行副总裁。从2012年到2016年，Toledano女士担任MLV&Co.（被B.Riley FBR&Co.收购）的梦百合投资银行业务主管，在那里她完成了总价值超过40亿美元的股票资本市场交易。加入MLV之前，从2004年到2010年，Toledano女士在Royalty Pharma的投资集团任职，该公司是一家领先的投资公司，拥有超过150亿美元的生物治疗特许权使用费资产。从1998年到2003年，Toledano女士领导安永会计师事务所（Ernst&Young）（以色列）的生命科学公司财务集团。Toledano女士拥有塔夫茨大学（Tufts University）经济学学士学位和纽约大学斯特恩商学院（NYU Stern School of Business）金融与创业工商管理硕士学位。
Miranda J. Toledano has served as the Company's Chief Executive Officer since July 2022 and as member of Entera Bio Ltd. Board of Directors since September 2018. Ms. Toledano has over 25 years of C level leadership, principal investment and Wall Street/capital market experience in the biotech sector. Previously, Miranda served as Chief Operating Officer, Chief Financial Officer, and Director of TRIGR Therapeutics, a stealth oncology focused, clinical stage bispecific antibody company, from August 2018 until its acquisition by Compass Therapeutics (Nasdaq: CMPX) in June 2021. At TRGR, Miranda oversaw the clinical development of lead asset TR009 (now tovecimig) and led strategic execution, including a $117 million China License Transaction and TRIGR's 2021 acquisition by CMPX. Previously, Ms. Toledano served as Head of Healthcare Investment Banking at MLV & Co. (acquired by B. Riley FBR & Co.), where she completed biotech equity financings (IPOs, ATMs, and follow ons) totaling over $4 billion in aggregate value. Earlier in her career, Ms. Toledano served as vice president in the investment group of Royalty Pharma (Nasdaq: RPRX) from 2004 to 2010. Ms. Toledano is also a member of the board of directors of Journey Medical (Nasdaq: DERM). Ms. Toledano holds a B.A. in Economics from Tufts University and an MBA in Finance and Entrepreneurship from the NYU Stern School of Business. - MirandaJ.Toledano自2018年9月以来一直担任我们的董事会成员。Toledano女士担任Trigr Therapeutics（一家临床阶段免疫肿瘤公司，专注于双特异性抗体）的首席运营官/首席财务官。此前，从2016年9月至2017年8月，Toledano女士担任Sorrento Therapeutics NASDAQ:SRNE的执行管理团队执行副总裁。从2012年到2016年，Toledano女士担任MLV&Co.（被B.Riley FBR&Co.收购）的梦百合投资银行业务主管，在那里她完成了总价值超过40亿美元的股票资本市场交易。加入MLV之前，从2004年到2010年，Toledano女士在Royalty Pharma的投资集团任职，该公司是一家领先的投资公司，拥有超过150亿美元的生物治疗特许权使用费资产。从1998年到2003年，Toledano女士领导安永会计师事务所（Ernst&Young）（以色列）的生命科学公司财务集团。Toledano女士拥有塔夫茨大学（Tufts University）经济学学士学位和纽约大学斯特恩商学院（NYU Stern School of Business）金融与创业工商管理硕士学位。
- Miranda J. Toledano has served as the Company's Chief Executive Officer since July 2022 and as member of Entera Bio Ltd. Board of Directors since September 2018. Ms. Toledano has over 25 years of C level leadership, principal investment and Wall Street/capital market experience in the biotech sector. Previously, Miranda served as Chief Operating Officer, Chief Financial Officer, and Director of TRIGR Therapeutics, a stealth oncology focused, clinical stage bispecific antibody company, from August 2018 until its acquisition by Compass Therapeutics (Nasdaq: CMPX) in June 2021. At TRGR, Miranda oversaw the clinical development of lead asset TR009 (now tovecimig) and led strategic execution, including a $117 million China License Transaction and TRIGR's 2021 acquisition by CMPX. Previously, Ms. Toledano served as Head of Healthcare Investment Banking at MLV & Co. (acquired by B. Riley FBR & Co.), where she completed biotech equity financings (IPOs, ATMs, and follow ons) totaling over $4 billion in aggregate value. Earlier in her career, Ms. Toledano served as vice president in the investment group of Royalty Pharma (Nasdaq: RPRX) from 2004 to 2010. Ms. Toledano is also a member of the board of directors of Journey Medical (Nasdaq: DERM). Ms. Toledano holds a B.A. in Economics from Tufts University and an MBA in Finance and Entrepreneurship from the NYU Stern School of Business.
- Sean Ellis
-
Sean Ellis自2019年6月以来一直担任我们的董事会成员。Ellis先生是Centillion基金的基金经理，这是一家致力于以色列投资的风险资本基金，主要专注于生物技术和梦百合行业的投资。Centillion公司是Entera Bio公司最早的投资者和最大股东之一。Ellis先生也是Redstone Capital的管理合伙人和创始人，Redstone Capital是一家技术风险投资基金，在东欧运营，由SBI Japan等资助。他持有New York University的文学学士学位，以及Columbia University的工商管理硕士学位。
Sean Ellis has served as a member of Entera Bio Ltd. Board since June 2019.Mr. Ellis is a fund manager of Centillion Fund, a venture capital fund dedicated to Israeli investments, with a primary focus on investments in the biotech and healthcare industries. Centillion is one of Entera Bio's earliest investors and largest shareholders. He holds a BA from New York University and MBA from Columbia University. - Sean Ellis自2019年6月以来一直担任我们的董事会成员。Ellis先生是Centillion基金的基金经理，这是一家致力于以色列投资的风险资本基金，主要专注于生物技术和梦百合行业的投资。Centillion公司是Entera Bio公司最早的投资者和最大股东之一。Ellis先生也是Redstone Capital的管理合伙人和创始人，Redstone Capital是一家技术风险投资基金，在东欧运营，由SBI Japan等资助。他持有New York University的文学学士学位，以及Columbia University的工商管理硕士学位。
- Sean Ellis has served as a member of Entera Bio Ltd. Board since June 2019.Mr. Ellis is a fund manager of Centillion Fund, a venture capital fund dedicated to Israeli investments, with a primary focus on investments in the biotech and healthcare industries. Centillion is one of Entera Bio's earliest investors and largest shareholders. He holds a BA from New York University and MBA from Columbia University.
- Haya Taitel
-
Haya Taitel，拥有超过30年的全球C级生物制药商业和战略执行经验。Taitel女士目前担任赛诺菲全球移植特许经营权的负责人，负责提高特许经营权的增长和盈利能力。在加入赛诺菲之前，Taitel女士曾担任Kadmon Pharmaceuticals，LLC的首席商务官，从2013年开始，她为Rezurock 的推出做出了贡献，直到该公司于2021年11月被赛诺菲以19亿美元的价格收购。Taitel女士还领导了Kadmon Board的执行商务委员会。从1997年开始，Taitel女士在强生公司担任了多个商业领导职位，在多个治疗领域，包括肿瘤学、免疫学、神经学和妇女医疗保健领域，职位越来越高。Taitel女士拥有天普大学的理学硕士学位、药理学硕士学位（药学等效性）和以色列耶路撒冷希伯来大学药学院的理学学士学位、药学学士学位和生物学学士学位。
Haya Taitel has served as a member of Entera Bio Ltd. Board since June 2023. Ms. Taitel has over 30 years of global C level biopharma commercial and strategic executive experience. She currently serves as the Head of Sanofi's Strategic Partnership and Portfolio Planning where she is responsible for increasing franchise growth and profitability. Prior to her role at Sanofi, Ms. Taitel served as the Chief Commercial Officer of Kadmon Pharmaceuticals, LLC, where she contributed to the launch of Rezurock, from 2013 until the company was acquired by Sanofi for $1.9 billion in November 2021. Ms. Taitel also led Kadmon Board's Executive Commercial Committee. Beginning in 1997, Ms. Taitel had held various commercial leadership positions of increasing seniority at Johnson and Johnson in multiple therapeutic areas, including oncology, immunology, neurology and women's healthcare. Ms. Taitel holds a Master of Science, Pharmacology, (PharmD equivalence) from Temple University and a Bachelor of Science, Pharmacy and Biology from the Hebrew University School of Pharmacy in Jerusalem, Israel. - Haya Taitel，拥有超过30年的全球C级生物制药商业和战略执行经验。Taitel女士目前担任赛诺菲全球移植特许经营权的负责人，负责提高特许经营权的增长和盈利能力。在加入赛诺菲之前，Taitel女士曾担任Kadmon Pharmaceuticals，LLC的首席商务官，从2013年开始，她为Rezurock 的推出做出了贡献，直到该公司于2021年11月被赛诺菲以19亿美元的价格收购。Taitel女士还领导了Kadmon Board的执行商务委员会。从1997年开始，Taitel女士在强生公司担任了多个商业领导职位，在多个治疗领域，包括肿瘤学、免疫学、神经学和妇女医疗保健领域，职位越来越高。Taitel女士拥有天普大学的理学硕士学位、药理学硕士学位（药学等效性）和以色列耶路撒冷希伯来大学药学院的理学学士学位、药学学士学位和生物学学士学位。
- Haya Taitel has served as a member of Entera Bio Ltd. Board since June 2023. Ms. Taitel has over 30 years of global C level biopharma commercial and strategic executive experience. She currently serves as the Head of Sanofi's Strategic Partnership and Portfolio Planning where she is responsible for increasing franchise growth and profitability. Prior to her role at Sanofi, Ms. Taitel served as the Chief Commercial Officer of Kadmon Pharmaceuticals, LLC, where she contributed to the launch of Rezurock, from 2013 until the company was acquired by Sanofi for $1.9 billion in November 2021. Ms. Taitel also led Kadmon Board's Executive Commercial Committee. Beginning in 1997, Ms. Taitel had held various commercial leadership positions of increasing seniority at Johnson and Johnson in multiple therapeutic areas, including oncology, immunology, neurology and women's healthcare. Ms. Taitel holds a Master of Science, Pharmacology, (PharmD equivalence) from Temple University and a Bachelor of Science, Pharmacy and Biology from the Hebrew University School of Pharmacy in Jerusalem, Israel.
- Steven D. Rubin
-
Steven D. Rubin，自企业于2009年10月合并，他担任董事会成员。他担任Ideation 的秘书从2007年6月至2009年10月。他一直是OPKO健康公司执行副总裁自2007年5月起，是OPKO健康公司的董事自2007年2月起，是冰霜集团有限责任公司（一家私人投资公司）的一员。他目前担任OPKO健康公司（一家专业的医疗保健公司），非侵入监测系统公司（一家医疗器械公司），Neovasc公司（血管器械开发商），Kidville公司（经营高档的儿童的学习和游乐设施），老虎X医药公司（前身为卡尔医药公司，前身是一家医疗器械公司），和城堡的品牌公司（高档白酒的营销商）的董事会成员。他曾担任梦公司（一家垂直整合的运动许可和产品的公司）， Ideation，TransEnterix公司（原SafeStitch医药公司）-一家医疗设备公司和PROLOR Biotech公司（一个发展阶段的生物制药公司）的董事会成员，在与OPKO健康公司合并之前。他曾任IVAX公司的高级副总裁，总法律顾问兼秘书从2001年8月至2006年9月。
Steven D. Rubin has served as OPKO Health's Executive Vice President – Administration since May 2007 and as a director since February 2007. He has extensive experience as a practicing lawyer, and as general counsel and board member to multiple public companies. Mr. Rubin currently serves on the board of directors of the following companies: Niagen Bioscience, Inc. (Nasdaq: NAGE), a bioscience company developing NAD+ products to support cellular health; Cocrystal Pharma, Inc. (NASDAQ:COCP), a biotechnology company developing new treatments for viral diseases; Eloxx Pharmaceuticals (NASDAQ: ELOX), a biotechnology company engaged in ribosomal RNA targeted genetic therapies for rare diseases; and Red Violet, Inc., (NASDAQ: RDVT) a leading analytics and information solutions provider. Mr. Rubin previously served as the Senior Vice President, General Counsel and Secretary of IVAX from August 2001 until September 2006. Mr. Rubin previously served as a director of the following companies: Neovasc, Inc. (NASDAQ:NVCN), a company developing and marketing medical specialty vascular devices; Non Invasive Monitoring Systems, Inc. (OTCBB:NIMU), a medical device company; Castle Brands, Inc. (NYSE:ROX), a developer and marketer of premium brand spirits; Kidville, Inc. (OTCBB:KVIL), an operator of large, upscale facilities, catering to newborns through five year old children and their families and offers a wide range of developmental classes for newborns to five year olds; VBI Vaccines Inc. (NASDAQ CM: VBIV), a commercial stage biopharmaceutical company developing a next generation of vaccines; Dreams, Inc. (NYSE MKT: DRJ), a vertically integrated sports licensing and products company; Safestitch Medical, Inc. prior to its merger with TransEnterix, Inc.; and, PROLOR Biotech, Inc.; and Cognit, Inc. (NASDAQ:COGT), a data and analytics company providing cloud based mission critical information and performance marketing solutions. Mr. Rubin holds a B.A. degree from Tulane University and a Juris Doctor from University of Florida. - Steven D. Rubin，自企业于2009年10月合并，他担任董事会成员。他担任Ideation 的秘书从2007年6月至2009年10月。他一直是OPKO健康公司执行副总裁自2007年5月起，是OPKO健康公司的董事自2007年2月起，是冰霜集团有限责任公司（一家私人投资公司）的一员。他目前担任OPKO健康公司（一家专业的医疗保健公司），非侵入监测系统公司（一家医疗器械公司），Neovasc公司（血管器械开发商），Kidville公司（经营高档的儿童的学习和游乐设施），老虎X医药公司（前身为卡尔医药公司，前身是一家医疗器械公司），和城堡的品牌公司（高档白酒的营销商）的董事会成员。他曾担任梦公司（一家垂直整合的运动许可和产品的公司）， Ideation，TransEnterix公司（原SafeStitch医药公司）-一家医疗设备公司和PROLOR Biotech公司（一个发展阶段的生物制药公司）的董事会成员，在与OPKO健康公司合并之前。他曾任IVAX公司的高级副总裁，总法律顾问兼秘书从2001年8月至2006年9月。
- Steven D. Rubin has served as OPKO Health's Executive Vice President – Administration since May 2007 and as a director since February 2007. He has extensive experience as a practicing lawyer, and as general counsel and board member to multiple public companies. Mr. Rubin currently serves on the board of directors of the following companies: Niagen Bioscience, Inc. (Nasdaq: NAGE), a bioscience company developing NAD+ products to support cellular health; Cocrystal Pharma, Inc. (NASDAQ:COCP), a biotechnology company developing new treatments for viral diseases; Eloxx Pharmaceuticals (NASDAQ: ELOX), a biotechnology company engaged in ribosomal RNA targeted genetic therapies for rare diseases; and Red Violet, Inc., (NASDAQ: RDVT) a leading analytics and information solutions provider. Mr. Rubin previously served as the Senior Vice President, General Counsel and Secretary of IVAX from August 2001 until September 2006. Mr. Rubin previously served as a director of the following companies: Neovasc, Inc. (NASDAQ:NVCN), a company developing and marketing medical specialty vascular devices; Non Invasive Monitoring Systems, Inc. (OTCBB:NIMU), a medical device company; Castle Brands, Inc. (NYSE:ROX), a developer and marketer of premium brand spirits; Kidville, Inc. (OTCBB:KVIL), an operator of large, upscale facilities, catering to newborns through five year old children and their families and offers a wide range of developmental classes for newborns to five year olds; VBI Vaccines Inc. (NASDAQ CM: VBIV), a commercial stage biopharmaceutical company developing a next generation of vaccines; Dreams, Inc. (NYSE MKT: DRJ), a vertically integrated sports licensing and products company; Safestitch Medical, Inc. prior to its merger with TransEnterix, Inc.; and, PROLOR Biotech, Inc.; and Cognit, Inc. (NASDAQ:COGT), a data and analytics company providing cloud based mission critical information and performance marketing solutions. Mr. Rubin holds a B.A. degree from Tulane University and a Juris Doctor from University of Florida.
- Geno J. Germano
-
Geno J. Germano自2017年11月起担任董事。Germano先生最近于2016年6月1日至2017年3月担任合成生物学领导者Intrexon Corporation的总裁。此前，他曾担任辉瑞公司全球创新制药业务的集团总裁，领导着价值140亿美元的全球业务，拥有市场领先的药物和多个治疗领域的广泛后期开发候选药物组合，包括心血管、代谢疾病、神经科学、炎症、免疫学、和罕见病。Germano先生还是辉瑞投资组合战略和投资委员会的联合主席，在此之前，他还担任辉瑞专业护理和肿瘤业务部门的总裁兼总经理。在加入辉瑞之前，Germano先生在惠氏制药担任过多个行政和领导职务，包括惠氏美国总裁，负责四个业务部门的运营成果交付，以及全球制药和女性医疗保健业务总裁。Germano先生一直是50国集团的成员，并在生物技术创新组织的董事会任职，担任执行委员会成员和国际委员会主席。他在医疗保健女企业家协会的艾瑞博德任职，并于2008年10月至2017年10月担任奥尔巴尼药学院的受托人，在那里他获得了药学理学学士学位。Germano先生以前是Zoetis公司的董事，目前是Bioverativ公司和Sage Therapeutics公司的董事。
Geno J. Germano Most recently, from August 2018 to June 2024, Mr. Germano served as President and Chief Executive Officer and a board member of Elucida Oncology, Inc., a biotechnology company. He previously served as President of Intrexon Corporation, or Intrexon, a leader in engineering and industrialization of biology, from June 2016 to March 2017. Prior to joining Intrexon, from 2014 to February 2016, Mr. Germano was Group President of the Global Innovative Pharma Business of Pfizer, where he led a growing global $14 billion business with market leading medicines and an extensive portfolio of late stage development candidates in several therapeutic areas. Mr. Germano was also Co Chair of the Portfolio Strategy and Investment Committee at Pfizer from 2013 to February 2016. Previously, from 2009 through 2013, Mr. Germano served as President and General Manager of Pfizer's Specialty Care and Oncology business units where he led commercial, medical, and post proof of concept pipeline strategy and development across global markets. Additionally, Mr. Germano has served on the board of directors of Precision Biosciences, Inc., a clinical stage biotechnology company, since March 2020. In the past five years, Mr. Germano served on the boards of directors of Sage Therapeutics (from 2016 until the company was acquired in 2025), Orbital Therapeutics, a private pre clinical stage biotechnology company (from March 2025 until the company was acquired in December 2025), Bioverativ Inc. (acquired by Sanofi S.A. in March 2018) and The Medicines Company (acquired by Novartis AG in January 2020). Mr. Germano received his B.S. in Pharmacy from Albany College of Pharmacy. - Geno J. Germano自2017年11月起担任董事。Germano先生最近于2016年6月1日至2017年3月担任合成生物学领导者Intrexon Corporation的总裁。此前，他曾担任辉瑞公司全球创新制药业务的集团总裁，领导着价值140亿美元的全球业务，拥有市场领先的药物和多个治疗领域的广泛后期开发候选药物组合，包括心血管、代谢疾病、神经科学、炎症、免疫学、和罕见病。Germano先生还是辉瑞投资组合战略和投资委员会的联合主席，在此之前，他还担任辉瑞专业护理和肿瘤业务部门的总裁兼总经理。在加入辉瑞之前，Germano先生在惠氏制药担任过多个行政和领导职务，包括惠氏美国总裁，负责四个业务部门的运营成果交付，以及全球制药和女性医疗保健业务总裁。Germano先生一直是50国集团的成员，并在生物技术创新组织的董事会任职，担任执行委员会成员和国际委员会主席。他在医疗保健女企业家协会的艾瑞博德任职，并于2008年10月至2017年10月担任奥尔巴尼药学院的受托人，在那里他获得了药学理学学士学位。Germano先生以前是Zoetis公司的董事，目前是Bioverativ公司和Sage Therapeutics公司的董事。
- Geno J. Germano Most recently, from August 2018 to June 2024, Mr. Germano served as President and Chief Executive Officer and a board member of Elucida Oncology, Inc., a biotechnology company. He previously served as President of Intrexon Corporation, or Intrexon, a leader in engineering and industrialization of biology, from June 2016 to March 2017. Prior to joining Intrexon, from 2014 to February 2016, Mr. Germano was Group President of the Global Innovative Pharma Business of Pfizer, where he led a growing global $14 billion business with market leading medicines and an extensive portfolio of late stage development candidates in several therapeutic areas. Mr. Germano was also Co Chair of the Portfolio Strategy and Investment Committee at Pfizer from 2013 to February 2016. Previously, from 2009 through 2013, Mr. Germano served as President and General Manager of Pfizer's Specialty Care and Oncology business units where he led commercial, medical, and post proof of concept pipeline strategy and development across global markets. Additionally, Mr. Germano has served on the board of directors of Precision Biosciences, Inc., a clinical stage biotechnology company, since March 2020. In the past five years, Mr. Germano served on the boards of directors of Sage Therapeutics (from 2016 until the company was acquired in 2025), Orbital Therapeutics, a private pre clinical stage biotechnology company (from March 2025 until the company was acquired in December 2025), Bioverativ Inc. (acquired by Sanofi S.A. in March 2018) and The Medicines Company (acquired by Novartis AG in January 2020). Mr. Germano received his B.S. in Pharmacy from Albany College of Pharmacy.
高管简历
中英对照 | 中文 | 英文- Hillel Galitzer
Hillel Galitzer自2014年2月以来一直担任我们的首席运营官，在此之前，从2012年7月开始担任我们的科学发展总监。Galitzer博士在医学研究和分子生物学方面有着十多年的经验。Galitzer从2010年8月到2014年2月担任Hadasit Bio Holdings Ltd.（特拉维夫证券交易所TASE:HDST and OTC Markets上市公司）分析师和首席运营官。他拥有超过10年的医学研究和分子生物学经验。他是Optivarial Inc.的联合创始人和前首席运营官。他在同行评审的期刊上撰写了许多出版物，并在国际会议和大学演讲和演讲。Galitzer博士在耶路撒冷希伯来大学医学院（Hebrew University Medical School）获得博士学位，在那里他接受了两位甲状旁腺激素和钙调节领域的世界知名研究人员的指导，他在以色列巴伊兰大学（Bar Ilan University）获得工商管理硕士学位，并获得医学学士学位。来自耶路撒冷的希伯来大学医学院。
Hillel Galitzer has served as Entera Bio Ltd. Chief Operating Officer since February 2014, prior to which he served as a Director of Scientific Development from July 2010. Prior to joining Entera, Dr. Galitzer was an analyst and the chief operating officer for Hadasit Bio Holdings Ltd., a publicly traded company on the Tel Aviv Stock Exchange (TASE: HDST) and OTC markets. He is the co founder and former chief operating officer of Optivasive Inc. Dr. Galitzer received his Ph.D. from the Hebrew University Medical School in Jerusalem, where he was mentored by two world renowned researchers in the areas of parathyroid hormone and calcium regulation, his M.B.A. from Bar Ilan University in Israel and his B.Med.Sc. from the Hebrew University Medical School in Jerusalem.- Hillel Galitzer自2014年2月以来一直担任我们的首席运营官，在此之前，从2012年7月开始担任我们的科学发展总监。Galitzer博士在医学研究和分子生物学方面有着十多年的经验。Galitzer从2010年8月到2014年2月担任Hadasit Bio Holdings Ltd.（特拉维夫证券交易所TASE:HDST and OTC Markets上市公司）分析师和首席运营官。他拥有超过10年的医学研究和分子生物学经验。他是Optivarial Inc.的联合创始人和前首席运营官。他在同行评审的期刊上撰写了许多出版物，并在国际会议和大学演讲和演讲。Galitzer博士在耶路撒冷希伯来大学医学院（Hebrew University Medical School）获得博士学位，在那里他接受了两位甲状旁腺激素和钙调节领域的世界知名研究人员的指导，他在以色列巴伊兰大学（Bar Ilan University）获得工商管理硕士学位，并获得医学学士学位。来自耶路撒冷的希伯来大学医学院。
- Hillel Galitzer has served as Entera Bio Ltd. Chief Operating Officer since February 2014, prior to which he served as a Director of Scientific Development from July 2010. Prior to joining Entera, Dr. Galitzer was an analyst and the chief operating officer for Hadasit Bio Holdings Ltd., a publicly traded company on the Tel Aviv Stock Exchange (TASE: HDST) and OTC markets. He is the co founder and former chief operating officer of Optivasive Inc. Dr. Galitzer received his Ph.D. from the Hebrew University Medical School in Jerusalem, where he was mentored by two world renowned researchers in the areas of parathyroid hormone and calcium regulation, his M.B.A. from Bar Ilan University in Israel and his B.Med.Sc. from the Hebrew University Medical School in Jerusalem.
- Dana Yaacov Garbeli
自2019年6月以来，Dana Yaacov Garbeli一直担任我们驻以色列的首席财务官。Yaacov-Garbeli女士目前是A2Z Finance Ltd的合伙人，在那里她担任私人和上市公司的外包首席财务官，并提供额外的咨询和会计服务。Yaacov-Garbeli女士此前曾在普华永道以色列公司（PricewaterhouseCoopers Israel）任职，包括短期借调到普华永道纽约公司（PricewaterhouseCoopers New York）担任高级经理，负责审计总部位于以色列，美国和欧洲的公共和私人持有的跨国公司，主要是制药和生物技术部门。Yaacov-Garbeli女士拥有管理与学术研究学院（College of Management and Academic Studies）的会计与商业管理学士学位和财务管理工商管理硕士学位。Yaacov-Garbeli女士是以色列的一名注册会计师。
Dana Yaacov Garbeli has served as Entera Bio Ltd. Chief Financial Officer since June 2019. Ms. Yaacov Garbeli has over 17 years of finance and accounting experience. She previously served as Senior Manager at PwC Israel overseeing audits of public and private companies.Ms. Yaacov Garbeli holds a B.A in accounting and business management and an MBA in financial management from The College of Management and Academic studies. Ms. Yaacov Garbeli is a Certified Public Accountant in Israel.- 自2019年6月以来，Dana Yaacov Garbeli一直担任我们驻以色列的首席财务官。Yaacov-Garbeli女士目前是A2Z Finance Ltd的合伙人，在那里她担任私人和上市公司的外包首席财务官，并提供额外的咨询和会计服务。Yaacov-Garbeli女士此前曾在普华永道以色列公司（PricewaterhouseCoopers Israel）任职，包括短期借调到普华永道纽约公司（PricewaterhouseCoopers New York）担任高级经理，负责审计总部位于以色列，美国和欧洲的公共和私人持有的跨国公司，主要是制药和生物技术部门。Yaacov-Garbeli女士拥有管理与学术研究学院（College of Management and Academic Studies）的会计与商业管理学士学位和财务管理工商管理硕士学位。Yaacov-Garbeli女士是以色列的一名注册会计师。
- Dana Yaacov Garbeli has served as Entera Bio Ltd. Chief Financial Officer since June 2019. Ms. Yaacov Garbeli has over 17 years of finance and accounting experience. She previously served as Senior Manager at PwC Israel overseeing audits of public and private companies.Ms. Yaacov Garbeli holds a B.A in accounting and business management and an MBA in financial management from The College of Management and Academic studies. Ms. Yaacov Garbeli is a Certified Public Accountant in Israel.
- Miranda J. Toledano
MirandaJ.Toledano自2018年9月以来一直担任我们的董事会成员。Toledano女士担任Trigr Therapeutics（一家临床阶段免疫肿瘤公司，专注于双特异性抗体）的首席运营官/首席财务官。此前，从2016年9月至2017年8月，Toledano女士担任Sorrento Therapeutics NASDAQ:SRNE的执行管理团队执行副总裁。从2012年到2016年，Toledano女士担任MLV&Co.（被B.Riley FBR&Co.收购）的梦百合投资银行业务主管，在那里她完成了总价值超过40亿美元的股票资本市场交易。加入MLV之前，从2004年到2010年，Toledano女士在Royalty Pharma的投资集团任职，该公司是一家领先的投资公司，拥有超过150亿美元的生物治疗特许权使用费资产。从1998年到2003年，Toledano女士领导安永会计师事务所（Ernst&Young）（以色列）的生命科学公司财务集团。Toledano女士拥有塔夫茨大学（Tufts University）经济学学士学位和纽约大学斯特恩商学院（NYU Stern School of Business）金融与创业工商管理硕士学位。
Miranda J. Toledano has served as the Company's Chief Executive Officer since July 2022 and as member of Entera Bio Ltd. Board of Directors since September 2018. Ms. Toledano has over 25 years of C level leadership, principal investment and Wall Street/capital market experience in the biotech sector. Previously, Miranda served as Chief Operating Officer, Chief Financial Officer, and Director of TRIGR Therapeutics, a stealth oncology focused, clinical stage bispecific antibody company, from August 2018 until its acquisition by Compass Therapeutics (Nasdaq: CMPX) in June 2021. At TRIGR, Miranda oversaw the clinical development of lead asset TR009 (now tovecimig) and led strategic execution, including a $117 million China License Transaction and TRIGR's 2021 acquisition by CMPX. Previously, Ms. Toledano served as Head of Healthcare Investment Banking at MLV & Co. (acquired by B. Riley FBR & Co.), where she completed biotech equity financings (IPOs, ATMs, and follow ons) totaling over $4 billion in aggregate value. Earlier in her career, Ms. Toledano served as vice president in the investment group of Royalty Pharma (Nasdaq: RPRX) from 2004 to 2010. Ms. Toledano is also a member of the board of directors of Journey Medical (Nasdaq: DERM). Ms. Toledano holds a B.A. in Economics from Tufts University and an MBA in Finance and Entrepreneurship from the NYU Stern School of Business.- MirandaJ.Toledano自2018年9月以来一直担任我们的董事会成员。Toledano女士担任Trigr Therapeutics（一家临床阶段免疫肿瘤公司，专注于双特异性抗体）的首席运营官/首席财务官。此前，从2016年9月至2017年8月，Toledano女士担任Sorrento Therapeutics NASDAQ:SRNE的执行管理团队执行副总裁。从2012年到2016年，Toledano女士担任MLV&Co.（被B.Riley FBR&Co.收购）的梦百合投资银行业务主管，在那里她完成了总价值超过40亿美元的股票资本市场交易。加入MLV之前，从2004年到2010年，Toledano女士在Royalty Pharma的投资集团任职，该公司是一家领先的投资公司，拥有超过150亿美元的生物治疗特许权使用费资产。从1998年到2003年，Toledano女士领导安永会计师事务所（Ernst&Young）（以色列）的生命科学公司财务集团。Toledano女士拥有塔夫茨大学（Tufts University）经济学学士学位和纽约大学斯特恩商学院（NYU Stern School of Business）金融与创业工商管理硕士学位。
- Miranda J. Toledano has served as the Company's Chief Executive Officer since July 2022 and as member of Entera Bio Ltd. Board of Directors since September 2018. Ms. Toledano has over 25 years of C level leadership, principal investment and Wall Street/capital market experience in the biotech sector. Previously, Miranda served as Chief Operating Officer, Chief Financial Officer, and Director of TRIGR Therapeutics, a stealth oncology focused, clinical stage bispecific antibody company, from August 2018 until its acquisition by Compass Therapeutics (Nasdaq: CMPX) in June 2021. At TRIGR, Miranda oversaw the clinical development of lead asset TR009 (now tovecimig) and led strategic execution, including a $117 million China License Transaction and TRIGR's 2021 acquisition by CMPX. Previously, Ms. Toledano served as Head of Healthcare Investment Banking at MLV & Co. (acquired by B. Riley FBR & Co.), where she completed biotech equity financings (IPOs, ATMs, and follow ons) totaling over $4 billion in aggregate value. Earlier in her career, Ms. Toledano served as vice president in the investment group of Royalty Pharma (Nasdaq: RPRX) from 2004 to 2010. Ms. Toledano is also a member of the board of directors of Journey Medical (Nasdaq: DERM). Ms. Toledano holds a B.A. in Economics from Tufts University and an MBA in Finance and Entrepreneurship from the NYU Stern School of Business.
- Gregory Burshtein
Gregory Burshtein，自2012年9月加入Entera以来一直在公司领导研发工作，担任药物研发总监，自2024年5月起担任Entera Bio Ltd.研发主管。Burshtein博士是口服递送多肽领域的领导者，发表在同行评审期刊上，拥有25项已发布专利，并拥有113项与口服大分子的开发、配方和递送相关的未决专利申请。Burshtein博士在药物递送、药理学和生物制药领域拥有超过20年的经验，主要专注于治疗肽口服递送这一具有挑战性的领域。Burshtein博士在耶路撒冷希伯来大学医学院药物研究所获得药学博士学位、临床药学理学理学硕士学位和B.药学学位。
Gregory Burshtein has led research and development at the Company since he joined Entera in September 2012, as Director of Pharmaceutical R&D, and since May 2024, as Entera Bio Ltd. Chief of Research and Development. Dr. Burshtein is a leader in the field of oral delivery of peptides, has published in peer reviewed journal articles and holds 25 issued patents and has 113 pending patent applications related to development, formulation, and delivery of oral large molecules. Dr. Burshtein holds over 20 years of experience in the field of drug delivery, pharmacology and biopharmaceutics, with a primary focus on the challenging area of oral delivery of therapeutic peptides. in this field. Dr. Burshtein obtained his Ph.D. in Pharmaceutical Sciences, MSc in Clinical Pharmacy, and B. Pharm degree from the Institute for Drug Research, Faculty of Medicine of the Hebrew University of Jerusalem.- Gregory Burshtein，自2012年9月加入Entera以来一直在公司领导研发工作，担任药物研发总监，自2024年5月起担任Entera Bio Ltd.研发主管。Burshtein博士是口服递送多肽领域的领导者，发表在同行评审期刊上，拥有25项已发布专利，并拥有113项与口服大分子的开发、配方和递送相关的未决专利申请。Burshtein博士在药物递送、药理学和生物制药领域拥有超过20年的经验，主要专注于治疗肽口服递送这一具有挑战性的领域。Burshtein博士在耶路撒冷希伯来大学医学院药物研究所获得药学博士学位、临床药学理学理学硕士学位和B.药学学位。
- Gregory Burshtein has led research and development at the Company since he joined Entera in September 2012, as Director of Pharmaceutical R&D, and since May 2024, as Entera Bio Ltd. Chief of Research and Development. Dr. Burshtein is a leader in the field of oral delivery of peptides, has published in peer reviewed journal articles and holds 25 issued patents and has 113 pending patent applications related to development, formulation, and delivery of oral large molecules. Dr. Burshtein holds over 20 years of experience in the field of drug delivery, pharmacology and biopharmaceutics, with a primary focus on the challenging area of oral delivery of therapeutic peptides. in this field. Dr. Burshtein obtained his Ph.D. in Pharmaceutical Sciences, MSc in Clinical Pharmacy, and B. Pharm degree from the Institute for Drug Research, Faculty of Medicine of the Hebrew University of Jerusalem.